Medicon Valley Alliance are pleased to invite you to an exclusive Good Morning Meeting hosted by Theradex Oncology and Simsen Diagnostics on 18h of November 2025.
Designed specifically for pharmaceutical companies developing cancer therapies, this gathering offers an opportunity to gain actionable insights and explore innovative solutions for oncology clinical trials. Sharing the latest strategies for designing effective oncology studies, as well as actionable approaches for incorporating personalised, tumour-informed ctDNA analysis to enhance patient selection, monitoring, and trial outcomes, this event will equip you with practical knowledge to drive success in your oncology studies.
Why Attend?
– Gain practical strategies for developing clinical trials that maximise value from early design through to execution.
– Discover the impact of personalised ctDNA solutions, including improved patient selection, trial monitoring, and endpoint assessment.
– Engage in an interactive Q&A and discussions with industry experts and peers, addressing the specific challenges faced by small/medium sized oncology companies.
– Network with like-minded professionals.
Spaces are limited, so don’t miss this opportunity to connect, learn, and collaborate. Register now to secure your place and take the next step towards advancing your oncology clinical trials.
We look forward to welcoming you to Oncology Horizons Breakfast Meeting in Copenhagen!
Date: Tuesday, 18th November 2025
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Welcome & Opening Remarks Joint introduction from Theradex and Simsen Diagnostics. Overview of the morning, aims, and relevance for small and medium-sized oncology companies. |
| 9:15 | Session 1: Setting Up Your Value-Generating Clinical Strategy, presented by Theradex
|
| 9:35 | Session 2: Personalised ctDNA Solutions for Clinical Trials, presented by Simsen Diagnostics
|
| 9:55 | Interactive Q&A and Roundtable Discussion Open floor for questions, sharing of experiences, and exploring solutions to current challenges in oncology trials. |
| 10:10 | Closing Remarks & Next Steps Summary of key takeaways, contact opportunities, and invitations for follow-up meetings |
| 10:15 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Stefan Filges, Chief Technology Officer at Simsen Diagnostics
Stefan Filges serves as Chief Technology Officer at Simsen Diagnostics, where he leads technology development and innovation in the healthcare diagnostics sector. He holds a PhD from Sahlgrenska Academy at Gothenburg University, bringing deep academic research experience and scientific expertise to advancing diagnostic technologies. |
 |
Hans Rosen, Managing Director, Theradex Oncology
Since joining Theradex Oncology in 2019, Hans Rosén has been serving as the Managing Director for the company’s European operations. With a strong entrepreneurial background in the life sciences sector, he brings proven expertise in advancing cancer drug candidates, having successfully guided two from initial discovery through to first-in-human clinical trials. Before joining Theradex, Hans served as CEO for two publicly listed life science companies on the NASDAQ Stockholm stock exchange over a period of eight years. |
| Organized by | In collaboration with | |
 |
 |
 |